Qiao Jing, Yan Xiaoming
Department of Ophthalmology, Peking University First Hospital, Key Laboratory of vision Loss and Restoration, Ministry of Education, Beijing, People's Republic of China.
Clin Ophthalmol. 2013;7:1797-803. doi: 10.2147/OPTH.S33182. Epub 2013 Sep 9.
Meibomian gland dysfunction (MGD) is one of the most common diseases observed in clinics; it influences a great number of people, and is the leading cause of evaporative dry eye. Given the increased recognition of the importance of MGD, a great amount of attention has been paid to therapies targeting this condition. The traditional treatments of MGD consist of warm compresses and lid hygiene for removing an obstructed meibum, as well as antibiotics and anti-inflammatory agents to improve the quality of the meibum. However, each of these treatments has a different shortcoming and the treatment of MGD remains challenging. Despite the numerous possible treatment options for MGD, it is still difficult to obtain complete relief of signs and symptoms. This review focuses on current emerging treatment options for MGD including intraductal meibomian gland probing, emulsion eye drops containing lipids, the LipiFlow® thermal pulsation system, N-acetyl-cysteine, azithromycin, oral supplementation with omega-3 essential fatty acids, and cyclosporine A.
睑板腺功能障碍(MGD)是临床上最常见的疾病之一;它影响着大量人群,是蒸发型干眼的主要原因。鉴于对MGD重要性的认识不断提高,针对这种情况的治疗方法受到了大量关注。MGD的传统治疗方法包括热敷和睑缘清洁以清除阻塞的睑脂,以及使用抗生素和抗炎药来改善睑脂质量。然而,这些治疗方法都有不同的缺点,MGD的治疗仍然具有挑战性。尽管有许多针对MGD的可能治疗选择,但仍难以完全缓解体征和症状。本综述重点关注MGD当前新兴的治疗选择,包括导管内睑板腺探查、含脂质的乳液眼药水、LipiFlow®热脉动系统、N-乙酰半胱氨酸、阿奇霉素、口服补充ω-3必需脂肪酸和环孢素A。